Submissions

This brief endorses Bill C-224 because it will better protect the right to life, liberty and security of the person (Charter section 7) and the right to equality (Charter section 15).
Bill C-224 would amend the Food and Drugs Act to restore the clear and very necessary distinction between low-risk “natural health products” (NHPs) such as Vitamin D and herbal remedies, and high-risk “therapeutic products” such as pharmaceutical drugs and medical devices. This Bill reverses harmful changes introduced in the 2023 Budget Implementation Act (Bill C-47) that wrongfully reclassified NHPs as therapeutic products, thereby subjecting them to
draconian enforcement powers, including fines of up to $5 million per day.